What's hot
View all perspectives
What's Hot
Rheumatoid Arthritis Comorbidities
Dr. Jonathan Kay reviews rheumatoid arthritis studies presented on day at EULAR 2022. Specifically, he discusses abstracts OP0132, OP0135 and OP0138.
Watch video →
Increasing Secukinumab Dose in Ankylosing Spondylitis Nonresponders
Dr. Peter Nash discusses abstract OP0023 from EULAR 2022.
Watch video →
DMARDS, Prednisone, Pregnancy, OH MY!
Dr. Kathryn Dao discusses abstracts POS1405, POS0696 and OP0130 presented at the EULAR 2022 meeting. Watch more videos from EULAR 2022 here: https://rheumnow.com/videos.
Watch video →
Breathing New Insight into RA Interstitial Lung Disease
Dr. Jonathan Kay reviews EULAR 2022 abstracts OP0132, OP0306, and OP0307.
Watch video →
EULAR 2022 - Day 4 Faculty Panel Recap
Dr. David Liew and Dr. Jack Cush discuss day 4 of EULAR 2022. LB0001, LB0002, LB0004, and LB0006.
Watch video →
Getting to the Heart of JAK Inhibitors
Dr. Jonathan Kay reviews rheumatoid arthritis sessions and abstracts from day 3 at EULAR 2022. Abstracts reviewed: OP0266; OP0258; and OP0269.
Watch video →
EULAR 2022 - Day 3 Faculty Panel Recap
Drs. Jack Cush, Janet Pope, Aurelie Najm and Yuz Yusof discuss highlights from Day 3 of EULAR 2022.
Watch video →
Deucravacitinib at EULAR 2022
Dr. Peter Nash provides and update on the TYK2 inhibitor, Deucravacitinib with reports on: - Safety of Deucravacitinib https://bit.ly/3NtZQxe - Deucravacitinib in SLE https://bit.ly/3Mh5nG0
Watch video →
Dr. John Cush RheumNow
3 years 6 months ago
Yesterday the FDA approved baricitinib (Olumiant) as the first systemic treatment for Alopecia Areata. Approval based on 2 DBRPCT Trial AA-1, AA-2) - 32% & 35% of pts on Bari 4 mg regrew scalp hair coverage by wk 36. https://t.co/SU74OxI2BC https://t.co/2wluug1fj4
There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question.
Dr. John Cush RheumNow
3 years 6 months ago
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z
A retrospective cohort study has shown that outcomes in pregnant systemic lupus erythematosus (SLE) patients has significantly improved in the last decade, but there still is a high risk of adverse pregnancy outcomes (APO).
A retrospective Danish SLE cohort was used to identify pregnancies in SLE patients from a single center between January 2010 and October 2020.
Dr. John Cush RheumNow
3 years 6 months ago
JAKi not yet safe in pregnancy - theyre fetotoxic at high doses (animals). JAKi do cross placenta. ACR Guidelines: no position due to no data. 47 tofa Rheum & 15 UC maternal exposures - no signif probs. Paternal use of JAKi is ok.
https://t.co/pom5KD0qt7 https://t.co/djYHZ5LdcE https://t.co/47lfyZC4H3
Dr. John Cush RheumNow
3 years 6 months ago
Watch: The Microbiome in Spondyloarthritis
Can microbes trigger SpA/PsA?
https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp
Dr. John Cush RheumNow
3 years 6 months ago
Cluster study of 383 aPL+ pts showed 4 clusters:
Cluster 1 (138): w/ SLE & non-criteria Sxs
Cluster 2 (112): pts w/ CV risks
Cluster 3 (83): females w/ OB morbidity (BEST outcome)
Cluster 4 (50): lupus anticoagulant (+) (high freq of arterial thrombosis) https://t.co/HGRTceplsn https://t.co/ZDdwhCmj5r
The American College of Rheumatology applauds the Federal Trade Commission’s decision to investigate the business practices of pharmacy benefit managers (PBMs), which continue to increase PBM profit margins while placing the burden of skyrocketing drug costs on America’s most vulnerable patients, including those living with chronic and severe rheumatic diseases.
Dr. John Cush RheumNow
3 years 6 months ago
GLORIA Study Pred vs PBO in >65yrs RA x 2 years. 451 Pts & DAS28 4.5. 79% on DMARDs (14% biologics)
Upside: Lower DAS28 -0.37 & less Xray progression -1.7 Sharp units
Downside: 24% more AE (mild infxns), signif.small lowering of lumbar BMD -1%
You Decide
https://t.co/RRq0WcFsXz https://t.co/xLxjPPSMhh
Dr. John Cush RheumNow
3 years 6 months ago
MMWR: Monkeypox Outbreak in Nine States
CDC is tracking multiple reported U.S. monkeypox cases, and monitoring cases in persons in countries without endemic monkeypox and with no known travel links to an endemic area.
https://t.co/Pr0n7pwAgS https://t.co/DvJtLq85E2
Dr. John Cush RheumNow
3 years 6 months ago
CV risk factors not equal when considering magnitude of risk
What can we learn from Oral Surveillance?
The Oral Surveillance trial has almost become a household word for rheumatologists.
https://t.co/LHZTVZh4AK https://t.co/2SlxrG7UpQ
Poster Hall